Hetero Ring Contains At Least Eight Members Patents (Class 424/9.363)
  • Patent number: 11097017
    Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 24, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Christian Preihs, Jing Yu, Veronica Clavijo Jordan, Yunkou Wu, Khaled Nasr, A. Dean Sherry, Sara Chirayil
  • Patent number: 11007283
    Abstract: The present invention relates to new class of functionalized polyazamacrocycles including at least one phosphonic or phosphinic group linked to a nitrogen atom of the macrocyclic cage, and capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: May 18, 2021
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Luciano Lattuada, Roberta Napolitano, Valeria Boi, Massimo Visigalli, Silvio Aime, Giovanni Battista Giovenzana, Alberto Fringuello Mingo
  • Patent number: 10968224
    Abstract: The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(II), Fe(II), Fe(III), Co(II) and Ni(II) complexes. The other subject of the invention is the application of the above compounds.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: April 6, 2021
    Assignee: DEBRECENI EGYETEM
    Inventors: Richárd Botár, Zoltán Garda, Tamás Fodor, Ferenc Krisztián Kálmán, Viktória Nagy, Gyula Tircsó, Imre Tóth
  • Patent number: 10969387
    Abstract: Compounds and complexes that can be useful as enterobactin probes not necessary are disclosed herein. Methods of detecting bacteria and/or methods of determining susceptibility of bacteria to an antibiotic using such compounds and complexes are also disclosed herein.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 6, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Valerie Christine Pierre, Sylvie Pailloux
  • Patent number: 10960088
    Abstract: Provided are macrocyclic compounds and iron or cobalt coordinated macrocyclic compounds. The compounds can be used as MRI contrast agents. Certain compounds are redox active and can be used to assess the biological redox status of a sample.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 30, 2021
    Assignees: The Research Foundation for The State University of New York, Health Research, Inc.
    Inventors: Janet R. Morrow, Pavel B. Tsitovich, Sarina J. Dorazio, Abiola O. Olatunde, Joseph A. Spernyak, Patrick Burns, Eric M. Snyder, Christopher J. Bond
  • Patent number: 10791989
    Abstract: A non-invasive imaging approach using CEST and MRS may be used to monitor the cleavage of the poly-L-glutamate (PLG) backbone. The cleavage of PLG by cathespsin B can expose exchangeable —NH2 protons in the PLG that are then monitored non-invasively through CEST. The technique can provide direct information on malignant tissue and tumor aggressiveness, and can also be used to monitor treatment.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 6, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mohammad Haris, Anup Singh, Kejia Cai, Ravinder Reddy, Feliks Kogan, Ravi Prakash Reddy Nanga, Hari Hariharan
  • Patent number: 10722601
    Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 28, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
  • Patent number: 10696694
    Abstract: The invention relates to cationic complexes made up of a lanthanide ion Ln3+ and a ligand of formula (I): with X, Y and R1 as defined in claim 1, and to the salts thereof with an anion, the solvates and hydrates thereof; with the exception of cationic complexes made up of a lanthanide ion Ln3+ and a ligand of one of formulae (I.1) or (I.4) as defined in claim 1, and the salts, solvates and hydrates thereof. The invention also relates to the use of such a complex or of a cationic complex made up of a lanthanide ion Ln3+ and a ligand of formula (I.1) or (I.4) as defined in claim 1, or of one of the salts thereof with an anion, the solvates or hydrates thereof, as an aid to the crystallisation of a biological macromolecule, as well as to crystallisation methods and methods for analysing or determining the structure of a biological macromolecule.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignees: ECOLE NORMALE SUPERIEURE LE LYON, UNIVERSITE CLAUDE BERNARD LYON I, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Oliver Maury, Eric Girard, Sylvain Engilberge, François Riobe
  • Patent number: 10653804
    Abstract: Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: May 19, 2020
    Assignee: Inventure, LLC
    Inventors: Richard Deslauriers, Jonathan Balfour, Michael Milbocker
  • Patent number: 9785923
    Abstract: A new electronic financial transaction (EFT) system is proposed, wherein the business logic of a transaction is defined at a location remote from a secure point of sale terminal, thus having a framework wherein the business logic can be easily customized or updated.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: October 10, 2017
    Assignee: INGENICO LIMITED
    Inventor: Dmitry Barsukov
  • Patent number: 9562038
    Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: February 7, 2017
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, Christopher Parker
  • Patent number: 9446157
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: September 20, 2016
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Patent number: 9352056
    Abstract: The present invention relates to a method for preparing a pharmaceutical formulation of lanthanide chelate in powder form, wherein the powder constitutes a mol/mol excess of free chelate of between 0.002 and 0.4%.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: May 31, 2016
    Assignee: GUERBET
    Inventor: Marc Port
  • Patent number: 8945512
    Abstract: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a paramagnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium (111), thulium (III), ytterbium (III) and europium (111).
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: February 3, 2015
    Assignee: Bracco Imaging SpA
    Inventors: Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Giovanni Battista Giovenzana
  • Patent number: 8945514
    Abstract: The invention relates to contrast agents for magnetic resonance imaging comprising a chelating ligand and a transition metal ion, said ligand carrying a substituent capable of reacting chemically or biochemically with a target substance while bringing about a change in the spin state.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: February 3, 2015
    Assignees: Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon
    Inventor: Jens Hasserodt
  • Patent number: 8911710
    Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: December 16, 2014
    Assignees: Agency for Science, Technology and Research, Nanyang Technological University
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang
  • Publication number: 20140363376
    Abstract: In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Xiankai SUN, Amit Kumar, Zoltan Kovacs
  • Publication number: 20140343402
    Abstract: The present invention generally relates to a composition comprising acetic anhydride, a DNP agent and a gadolinium complex and its use for the preparation of hyperpolarised imaging agent for MR diagnostic analysis.
    Type: Application
    Filed: December 3, 2012
    Publication date: November 20, 2014
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Silvio Aime, Sonia Colombo Serra, Pernille Rose Jensen, Magnus Karlsson, Mathilde H. Lerche, Fabio Tedoldi, Massimo Visigalli
  • Publication number: 20140271490
    Abstract: The present invention relates to bacteria-targeted contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to bacteria targeted MRI contrast agents that can be used to detect bacteria in vivo or in vitro. In certain embodiments, the contrast agents comprise a metal chelate conjugated to at least two Zn-dipicolylamine groups.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 18, 2014
    Applicant: Northwestern University
    Inventors: Lauren M. Matosziuk, Allison S. Harney, Keith W. MacRenaris, Thomas J. Meade
  • Patent number: 8815213
    Abstract: RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.
    Type: Grant
    Filed: March 1, 2009
    Date of Patent: August 26, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Avigdor Scherz, Liat Goldshaid, Yoram Salomon
  • Publication number: 20140193344
    Abstract: Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the compounds can be used MRI paraCEST contrast agents.
    Type: Application
    Filed: May 11, 2012
    Publication date: July 10, 2014
    Applicant: The Research Foundation of State University of New York
    Inventors: Janet R. Morrow, Pavel Tsitovich, Sarina Dorazio, Abiola Olatunde
  • Patent number: 8758726
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: June 24, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Patent number: 8758723
    Abstract: The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N4 compounds and derivatives.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: June 24, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David J. Yang, Chang-Sok Oh, Dong-Fang Yu, Ali Azhdarinia, Saady Kohanim
  • Patent number: 8734761
    Abstract: The invention provides MRI contrast agents which provide a high sensitivity and which have an optimised body retention time. These agents enable the mapping of the local pH, temperature, oxygen concentration or other metabolites in a patient's body by the use of Chemical Exchange Saturation Transfer (CEST). Particularly pH and temperature mapping are useful for the detection of small cancer lesions and localized inflammation respectively.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: May 27, 2014
    Assignee: Koninklijke Philips N.V.
    Inventors: Nicolaas Petrus Willard, Rene Theodorus Wegh, Jeroen Alphons Pikkemaat, Holger Gruell
  • Patent number: 8697034
    Abstract: The present invention relates to the preparation of hyperpolarized 89Y. Hyperpolarized 89Y may be used as nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI) agents for sensitive detection and imaging.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 15, 2014
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Zoltan Kovacs, Matthew E. Merritt, A. Dean Sherry
  • Publication number: 20140065075
    Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion is for binding to necrotic tissue in the subject.
    Type: Application
    Filed: April 17, 2012
    Publication date: March 6, 2014
    Applicant: RF THERAPEUTICS INC.
    Inventors: Jidong Zhang, Kenneth Curry
  • Publication number: 20130336898
    Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicant: GUERBET
    Inventors: Dominique MEYER, Claire COROT, Marc PORT, Vincent BARBOTIN, Bruno BONNEMAIN
  • Publication number: 20130315822
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 28, 2013
    Applicant: Lantheus Medical Imaging, Inc.
    Inventor: Lantheus Medical Imaging, Inc.
  • Publication number: 20130302258
    Abstract: The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 14, 2013
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Thomas J. Meade, Renee C. Strauch, Luke F. Vistain
  • Patent number: 8580231
    Abstract: The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: November 12, 2013
    Assignee: Northwestern University
    Inventors: Preeti A. Sukerkar, Jiyoun Lee, Teresa K. Woodruff, Thomas J. Meade
  • Publication number: 20130195768
    Abstract: The present invention relates to the use of non-equivalent mobile protons belonging to NMR distinguishable steroisomers of a CEST agent in a ratiometric based CEST imaging procedure and to Lanthanide (III) complex compounds displaying at least two NMR-distinguishable steroisomers in solution useful as concentration independent CEST responsive agents.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 1, 2013
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Silvio Aime, Daniela Delli Castelli, Franco Fedeli, Dario Livio Longo, Enzo Terreno, Fulvio Uggeri
  • Patent number: 8460636
    Abstract: Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: June 11, 2013
    Assignee: Japan Science and Technology Agency
    Inventors: Koji Suzuki, Hiroki Hifumi, Akihiro Tanimoto, Megumi Makino
  • Publication number: 20130142735
    Abstract: A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity.
    Type: Application
    Filed: January 31, 2013
    Publication date: June 6, 2013
    Inventors: Balaraman Kalyanaraman, Joy Joseph, Kathleen Marie Schmainda, Douglas Edward Prah, Marcos Lopez, Micael Joel Hardy
  • Patent number: 8404216
    Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m-X1p1X2p2X3p3X4p4]z?zB+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: March 26, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite Louis Pasteur
    Inventors: Delphine Felder-Flesch, Jérôme Steibel, Annabelle Bertin
  • Publication number: 20130011340
    Abstract: The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 10, 2013
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Preeti A. Sukerar, Jiyoun Lee, Teresa K. Woodruff, Thomas J. Meade
  • Patent number: 8323621
    Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: December 4, 2012
    Assignees: Vanderbilt University, Texas Tech University System
    Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
  • Publication number: 20120244081
    Abstract: The present invention relates to manganese(II) chelates. The invention also relates to said manganese(II) chelates attached to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).
    Type: Application
    Filed: December 17, 2010
    Publication date: September 27, 2012
    Inventor: Andreas Meijer
  • Patent number: 8182806
    Abstract: Synovial villi derived explants and related surgical tools used to repair or prevent damage to injured or diseased tissue, including connective tissue. The tools including a harvesting tool for selectively harvesting synovial villi from the joint of patient and a delivery tool having a bulbous end for delivering the synovial villi derived explants while reducing damage to surrounding tissue.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: May 22, 2012
    Inventor: Lanny L. Johnson
  • Publication number: 20120107248
    Abstract: This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility.
    Type: Application
    Filed: June 28, 2010
    Publication date: May 3, 2012
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Adil E. Bharucha, Abdul H. Fauq
  • Publication number: 20120093735
    Abstract: Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined.
    Type: Application
    Filed: December 29, 2011
    Publication date: April 19, 2012
    Inventors: Koji SUZUKI, Hiroki Hifumi, Akihiro Tanimoto, Megumi Makino
  • Publication number: 20120082624
    Abstract: The present invention relates to a method for preparing a pharmaceutical formulation of lanthanide chelate in powder form, this powder comprising a mol/mol excess of free chelate of between 0.002 and 0.4%, said method comprising the following successive steps: 1) step 1: mixing the chelate and the lanthanide so as to obtain complexation of the lanthanide by the chelate, the complexation solution obtained comprising, in addition to the chelate-lanthanide complex, an excess amount X1 of free chelate; 2) step 2: preferably measuring X1; 3) step 3: precipitating the complexation solution obtained in step 1) from an organic solvent so as to obtain a powder of chelate-lanthanide complex, the powder containing an excess amount X2 of free chelate; 4) step 4: optionally adjusting X2 so as to obtain: 4.a) X2 is between 0.002 and 0.4%, and more especially between 0.02 and 0.3% mol/mol, very advantageously between 0.025 and 0.25% mol/mol, 4.b) X2 corresponds to between 0.2 and 2 times X1, in particular between 0.
    Type: Application
    Filed: May 12, 2010
    Publication date: April 5, 2012
    Applicant: GUERBET
    Inventor: Marc Port
  • Publication number: 20110268663
    Abstract: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 3, 2011
    Inventors: Roderick Wayland Bates, Xavier Golay, Changtong Yang
  • Patent number: 8017105
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: September 13, 2011
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Patent number: 8003078
    Abstract: MRI contrast agents that employ paramagnetic agents and chemical exchange saturation transfer (paraCEST) and which are coupled to targeted particulate delivery vehicles provide sufficient concentration of the paraCEST contrast agents to obtain useful images of target tissues or organs. In addition, the image contrast may be switched on or off with a presaturation radio frequency pulse, avoiding the necessity obtaining pre-injection and post-injection images.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: August 23, 2011
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Garry E. Kiefer, Phillip S. Athey
  • Publication number: 20110177008
    Abstract: The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes.
    Type: Application
    Filed: January 18, 2011
    Publication date: July 21, 2011
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Lisa M. Manus, Daniel J. Mastarone, Dean Ho, Thomas J. Meade
  • Publication number: 20110177009
    Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 21, 2011
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Sander Langereis, Jochen Keupp, Holger Gruell, Dirk Burdinski, Danielle Beelen
  • Publication number: 20110165089
    Abstract: Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined.
    Type: Application
    Filed: March 8, 2006
    Publication date: July 7, 2011
    Applicant: Japan Science and Technology Agency
    Inventors: Koji Suzuki, Hiroki Hifumi, Akihiro Tanimoto, Megumi Makino
  • Publication number: 20110129425
    Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.
    Type: Application
    Filed: February 18, 2009
    Publication date: June 2, 2011
    Inventors: Dominique Meyer, Claire Corot, Marc Port, Vincent Barbotin, Bruno Bonnemain
  • Patent number: 7906105
    Abstract: The present invention relates to contrast agents for magnetic resonance imaging (MRI). In particular, the present invention relates to MRI contrast agents that are activated in the presence of zinc(II) (e.g., resulting in a brighter image).
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: March 15, 2011
    Assignee: Northwestern University
    Inventors: Jody L. Major, Thomas J. Meade
  • Patent number: 7897140
    Abstract: Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e.g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3 to 6 —CH2CONHphenylCH2CH(N(CH2COOH)2))(CH2N(CH2COOH)(CH2CH2N(CH2COOH)2)) groups or esters thereof or complexes thereof with gadolinium(III).
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 1, 2011
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Lalit Goswami, Joseph Spernyak, Peter Kanter, Richard Mazurchuk